NCT06526364 Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
| NCT ID | NCT06526364 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-10 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-12-10 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 * Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations. * Signed informed consent form * In possession of a Healios+Me app compatible smartphone (iOS/Android) * Corrected close visual acuity of ≥0.5 * Hand motor skills sufficient for using a smartphone * Ability to follow the study procedures * Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (\< 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS). * Enrolled in the SMSC at University Hospital Basel There are no specific exclusion criteria.
Contact & Investigator
Cristina Granziera, Prof.
PRINCIPAL INVESTIGATOR
Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
Frequently Asked Questions
Who can join the NCT06526364 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06526364 currently recruiting?
Yes, NCT06526364 is actively recruiting participants. Contact the research team at bebeka.cosandey@usb.ch for enrollment information.
Where is the NCT06526364 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT06526364 clinical trial?
NCT06526364 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Cristina Granziera, Prof. at Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB). The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.